BRIEF-Bridgebio Says FDA Accepts NDA For BBP-418 With Priority Review For LGMD2I/R9

BridgeBio Pharma

BridgeBio Pharma

BBIO

0.00

May 27 (Reuters) - BridgeBio Pharma Inc BBIO.O:

  • ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NDA FOR BBP-418 FOR LGMD2I/R9

  • FDA ACCEPTS BRIDGEBIO NDA FOR BBP-418 WITH PRIORITY REVIEW FOR LGMD2I/R9

  • FDA SETS PDUFA TARGET ACTION DATE OF NOVEMBER 27, 2026 FOR BBP-418

  • FDA NOT PLANNING ADVISORY COMMITTEE MEETING FOR BBP-418 APPLICATION

Source text: ID:nGNX3BhQny

Further company coverage: BBIO.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.